LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

Search

Arbutus Biopharma Corp

Uždarymo kaina

3.45 -3.63

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.45

Max

3.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-12M

-25M

Pardavimai

190K

1.8M

Pelnas, tenkantis vienai akcijai

-0.182

Pelno marža

-1,390.363

Darbuotojai

44

EBITDA

-12M

-24M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+39.66% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

44M

686M

Ankstesnė atidarymo kaina

7.08

Ankstesnė uždarymo kaina

3.45

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Arbutus Biopharma Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-17 14:44; UTC

Įsigijimai, susijungimai, perėmimai

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

2025-06-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

2025-06-17 23:34; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

2025-06-17 23:22; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-17 23:22; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-06-17 23:22; UTC

Rinkos pokalbiai

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

2025-06-17 23:17; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

2025-06-17 23:05; UTC

Rinkos pokalbiai

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

2025-06-17 23:05; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-06-17 22:58; UTC

Rinkos pokalbiai

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

2025-06-17 22:55; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

2025-06-17 22:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

2025-06-17 22:14; UTC

Pagrindinės rinkos jėgos

Bitdeer Technologies Group Shares Fall on Note Offering

2025-06-17 19:49; UTC

Rinkos pokalbiai

Natural Gas Slow Down Gains -- Market Talk

2025-06-17 19:34; UTC

Rinkos pokalbiai

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

2025-06-17 19:10; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-17 19:10; UTC

Rinkos pokalbiai

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

2025-06-17 18:41; UTC

Rinkos pokalbiai

Slowdown in US Consumer Spending Expected -- Market Talk

2025-06-17 18:15; UTC

Rinkos pokalbiai

Gold Inches Down as Profit-Taking Seen -- Market Talk

2025-06-17 17:44; UTC

Rinkos pokalbiai

Analysts Forecast Record-High Ethanol Output -- Market Talk

2025-06-17 16:37; UTC

Rinkos pokalbiai

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

2025-06-17 16:30; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-17 16:30; UTC

Rinkos pokalbiai

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

2025-06-17 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-17 16:15; UTC

Rinkos pokalbiai

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

2025-06-17 16:12; UTC

Rinkos pokalbiai

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

2025-06-17 14:54; UTC

Rinkos pokalbiai

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

2025-06-17 14:47; UTC

Rinkos pokalbiai

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

2025-06-17 14:41; UTC

Rinkos pokalbiai

Natural Gas Extends Climb -- Market Talk

2025-06-17 14:40; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Arbutus Biopharma Corp Prognozė

Kainos tikslas

By TipRanks

39.66% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  39.66%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arbutus Biopharma Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.255 / 3.365Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.